News and Announcements
Proteomics International Laboratories Ltd CEO Interview
- Published February 04, 2015 12:19PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Proteomics International Laboratories Ltd (PILL) is an innovative biological research and drug discovery company specialising in the development of simple diagnostic tests for common diseases and the discovery of new therapeutic drugs to treat pain and infection. The Company, based in Perth, Western Australia, works across three units – diagnostics, therapeutics and analytical services.
The Company now seeks additional funding of $6 million to expand each business unit and accelerate commercialisation. It focuses on utilising the funds raised to commercialise the already-developed IP, and implement a measured programme for further compound discovery, whilst expanding existing revenues to underpin future efforts.
To find out more about PILL please listen to Dr Richard Lipscombe, Managing Director.
Executive Interviews
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
